ABOUT

CUREBIO

THERAPEUTICS


Curebio Therapeutics is engaged in the discovery and development of potential first-in-class medicines based  on newly discovered pathway effected by ARSs (Aminoacyl tRNA Synthetases)


·Translating novel biology ARS into first-in-class therapies

·MOA of our pipelines was published at eminent academic  journals

CEO

Hyo Sung Kwon, Ph.D


• ©NDFOS / Bio Business Division

• ©NEXEL Business / Development Team Manager

• ©Cellivery Therapeutics / Business Development Team Manager

• Korea University Biomedical Engineering Ph.D.


Director

Hae Sung Lee


•©CKD Research Institute 

•©Hanwha Dream Pharm. 

•©Bukwang Pharm.

•National Institute of Food and Drug Safety Evaluation

•Sungkyunkwan University Bio Engineering M.S.

Scientific Advisory Board

Prof. Roger Kornberg


•2006 Novel Prize Winner in Chemistry

•Stanford Medicine, Department of Structural Biology / Professor

•Stanford, Chemical Physics, Ph.D.

•Harvard, Chemistry, BSc


Scientific Advisory Board

Prof. Se Chan Kang


•Kyung Hee University / College of Life Sciences Prof. / Director of Institute of Biotechnology

•Head of Kyung Hee University Affiliated Biomedical Research Center

•University of Munich / Visitiing Prof.

•The Plant Resources Society of Korea / Vice President

•The Korean Society of Medicinal Crop / Executive Director

•Sungkyunkwan University Pharmacy Ph.D.

OUR SCIENCE

ARSs

BIOLOGY

ARSs are essential enzymes for protein synthesis with evolutionarily conserved enzymatic mechanisms. 

(ARSs ligate amino acids to their corresponding tRNAs.) 


ARS were originally thought to only play a role in protein syn

thesis but recent genomic and proteomic advances have unveiled hidden biological functions of ARSs beyond their catalytic roles. 


ARSs have potential for new therapeutic targets and agents through multiple avenues, including direct targeting of the catalytic sites and developing novel biologics from the secreted ARS protein or their peptides. 


[Nature reviews drug discovery 18, 629-650, 2019]

① Targeting catalytic sites

② Targeting PPls

③ Therapeutic potential of secreted ARSs

OUR SCIENCE

ARSs [Aminoacyl tRNA Synthetases]

BIOLOGY

ARSs are essential enzymes for protein synthesis with evolutionarily conserved enzymatic mechanisms. (ARSs ligate amino acids to their corresponding tRNAs.) 


ARS were originally thought to only play a role in protein synthesis but recent genomic and proteomic advances have unveiled hidden biological functions of ARSs beyond their catalytic roles. 


ARSs have potential for new therapeutic targets and agents through multiple avenues, including direct targeting of the catalytic sites and developing novel biologics from the secreted ARS protein or their peptides. 


[Nature reviews drug discovery 18, 629-650, 2019]

①  Targeting catalytic sites

② Targeting PPls

③ Therapeutic potential of secreted ARSs

Linkage map of ARSs with various human 

diseases

The diverse connections of ARSs with various human diseas

es make them attractive as targets for the development of therapeutics. Two of the synthetase-GRS and AIMP1 have been studied in detail for their alternative functions in cell signaling pathways at CurebioTX.


PNAS 32 : 11043-11049 (2008)


PUBLICATIONS

REVIEW

CBT 1424

CBT 2001/2004/2005

CBC 2002/2003

CBD 0901

PUBLICATIONS

REVIEW

CBT1424

CBT 2001 / 2004 / 2005

CBC 2002 / 2003

CBD 0901

INTELLECTUAL

PROPERTY

PATENTS

Curebio Therapeutics has built intellectual

property portfolio covering GRS and AIMP1 peptides


PATENTS

INTELLECTUAL

PROPERTY

Curebio Therapeutics has built intellectual

property portfolio covering GRS and AIMP1 peptides

R&D

PIPELINE

Currently CurebioTX  has three defined development projects, all based on our research on human proteins. Our two drug candidates, NeoPep GT and NeoPep A1H are small peptides. Glycyl-tRNA synthetase (GRS)-derived peptides (NeoPep GT) are a series of anti-tumorigenic peptides derived from the natural immune-surveillance agent, GRS. ARS-interacting multifunctional protein 1 (AIMP1)-derived peptides (NeoPep A1H) comprise a hair growth peptide derived from the natural anti-aging agent, AIMP1. The profile of each drug candidate is described in short in the following diagram.

ProgramIndicationResearchPreclinicalPhase1Phase2Phase3
CBT1424


Renal Cell Carcinoma*
Ovarian Cancer
Liver/Lung Cancer
CBT2004Alopecia
CBT2005Wound care
CBD0901Sepsis(Diagnostic)**Clinical trial for medical device
CBC2001Anti-aging
Commercially available for cosmetics
CBC2002Wrinkle care
Licence-out (INCI code: sh-oligopeptide 84)
CBC2003Whitening

Licence-out (INCI code: sh-oligopeptide 91 SP)

* In partnership with Neo TX

** In partnership with JW Bioscience



CUREBIOTX 

NEWS

관리자
2022-09-28
조회 53

test

CUREBIO THERAPEUTICS

We are a passionate and dynamic group of scientists, engineers, designers and business folk. 

Our goal: empower people to live healthier, longer.


Contact Details

Room 1201, AceGwanggyoTower2, Yeongtong-gu, Suwon, Gyeonggi, Korea (ZIP 16229)


E-mail: contact@curebiotx.com

CUREBIO THERAPEUTICS


We are a passionate and dynamic group of scientists, engineers, designers and business folk. 

Our goal: empower people to live healthier, longer.

Contact Details


Room 1201, AceGwanggyoTower2, 

Yeongtong-gu, Suwon, Gyeonggi, Korea 

(ZIP 16229)

E-mail


contact@curebiotx.com